Preferential phosphodiesterase inhibition as a novel strategy to modulate key pathways in systemic sclerosis
- 1Department of Rheumatology, University Hospital Düsseldorf, Heinrich Heine University , ,
- 2Division of Rheumatology and Immunology, Department of Internal Medicine, Vanderbilt University Medical Center, Tennessee Valley Healthcare System Veterans Affairs Medical Center , , ,
- 3Division of Rheumatology, UTHealth Houston , , ,
Abstract
Systemic sclerosis (SSc) is a complex autoimmune disease marked by vasculopathy, immune dysregulation, and progressive fibrosis of the skin and internal organs. The high disease burden and impact on quality of life highlight the need for therapies that target underlying pathogenic mechanisms rather than merely treating organ-specific symptoms. Phosphodiesterases, including phosphodiesterase 4B (PDE4B), are key regulators of cellular function and inflammatory responses of several cell types central to SSc pathogenesis. Given PDE4B’s broad effects, targeting it may provide benefits beyond organ-specific manifestations and improve current care. Selective PDE4B inhibition represents a novel therapeutic approach for SSc, with improved subtype selectivity compared with earlier pan-PDE4 inhibitors. Nerandomilast preferentially inhibits PDE4B (ninefold over PDE4D), potentially improving tolerability versus oral pan-PDE4 inhibitors by avoiding adverse events such as gastrointestinal intolerance. Preclinical findings in SSc-relevant mouse and cell models show that PDE4B inhibition modulates inflammatory cytokine secretion, smooth muscle cell tension, endothelial and epithelial barrier integrity, and extracellular matrix synthesis under oxidative stress; this suggests nerandomilast could attenuate immune dysregulation, fibrosis, and potentially impact vasculopathy. Two pivotal Phase III trials evaluated nerandomilast in patients with idiopathic pulmonary fibrosis (FIBRONEER™-IPF; NCT05321069) and progressive pulmonary fibrosis (FIBRONEER™-ILD; NCT05321082), the latter of which included patients with SSc-associated interstitial lung disease (SSc-ILD). The ongoing CONQUEST trial (NCT06195072) is investigating the efficacy and safety of various drugs, including nerandomilast, in patients with early active SSc-ILD. This perspective highlights the rationale for targeting PDE4B in SSc therapy and explores preclinical findings in SSc and clinical findings in SSc-ILD to date.
Related
- Breaking the link between demyelination and axon loss: SARM1 inhibition as a neuroprotective strategy for multiple sclerosis
- Bivalent CK2 Inhibition as a Potent Strategy Against SARS-CoV-2 and Other Coronaviruses
- Rhythmic-phasic c-di-AMP signaling: a new paradigm for bacterial growth synchronization governed by a pseudo-phosphodiesterase and modifiable diadenylate cyclase.
- The preferential targeting of the diseased microvasculature by disk-like particles
- Microtubule destabilization by SB225002 through preferential weakening of lateral tubulin interactions revealed by structural and computational analyses
BibTeX
@article{distler2026preferential,
title = {{Preferential phosphodiesterase inhibition as a novel strategy to modulate key pathways in systemic sclerosis}},
author = {Jörg H. W. Distler and Tracy Frech and Zsuzsanna H. McMahan},
journal = {Frontiers in immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1829186},
url = {https://europepmc.org/article/PMC/PMC13672333},
note = {CC BY},
}
RIS
TY - JOUR
TI - Preferential phosphodiesterase inhibition as a novel strategy to modulate key pathways in systemic sclerosis
AU - Jörg H. W. Distler
AU - Tracy Frech
AU - Zsuzsanna H. McMahan
PY - 2026
DA - 2026/10/02
JO - Frontiers in immunology
DO - 10.3389/fimmu.2026.1829186
UR - https://europepmc.org/article/PMC/PMC13672333
AB - Systemic sclerosis (SSc) is a complex autoimmune disease marked by vasculopathy, immune dysregulation, and progressive fibrosis of the skin and internal organs. The high disease burden and impact on quality of life highlight the need for therapies that target underlying pathogenic mechanisms rather than merely treating organ-specific symptoms. Phosphodiesterases, including phosphodiesterase 4B (PDE4B), are key regulators of cellular function and inflammatory responses of several cell types central to SSc pathogenesis. Given PDE4B’s broad effects, targeting it may provide benefits beyond organ-specific manifestations and improve current care. Selective PDE4B inhibition represents a novel therapeutic approach for SSc, with improved subtype selectivity compared with earlier pan-PDE4 inhibitors. Nerandomilast preferentially inhibits PDE4B (ninefold over PDE4D), potentially improving tolerability versus oral pan-PDE4 inhibitors by avoiding adverse events such as gastrointestinal intolerance. Preclinical findings in SSc-relevant mouse and cell models show that PDE4B inhibition modulates inflammatory cytokine secretion, smooth muscle cell tension, endothelial and epithelial barrier integrity, and extracellular matrix synthesis under oxidative stress; this suggests nerandomilast could attenuate immune dysregulation, fibrosis, and potentially impact vasculopathy. Two pivotal Phase III trials evaluated nerandomilast in patients with idiopathic pulmonary fibrosis (FIBRONEER™-IPF; NCT05321069) and progressive pulmonary fibrosis (FIBRONEER™-ILD; NCT05321082), the latter of which included patients with SSc-associated interstitial lung disease (SSc-ILD). The ongoing CONQUEST trial (NCT06195072) is investigating the efficacy and safety of various drugs, including nerandomilast, in patients with early active SSc-ILD. This perspective highlights the rationale for targeting PDE4B in SSc therapy and explores preclinical findings in SSc and clinical findings in SSc-ILD to date.
SN - 1664-3224
ER -